by Amirah Al Idrus | Feb 22, 2018 fiercebiotech.com One-fifth of patients in a phase 1 study responded to an investigational ERK inhibitor from Merck, bolstering hopes that this type of drug could be used effectively in combination with other cancer drugs. ERK is a cell signal that is believed to drive the growth of … Continue reading Merck’s ERK inhibitor shows promise in combo against resistant cancers
Meagan Ryan Awarded a NIH F31 grant
Meagan Ryan, of the Der and Cox labs, was recently awarded a NIH fellowship grant (F31) for her application entitled "Defining the Role of ERK1 and ERK2 in pancreatic cancer". The current focus of Ryan's research is ERK1/2 signalling in pancreatic cancer and melanoma. Well done Meagan!